The National Institute for Health and Care Excellence is endorsing the use of Bristol-Myers Squibb and Pfizer’s clotbuster Eliquis (apixaban) on the National Health Service in England and Wales.

In draft guidelines, the cost regulator has deemed Eliquis value for money when used for the treatment and prevention of venous thromboembolism (VTE) in adults.

The National Institute for Health and Care Excellence is endorsing the use of Bristol-Myers Squibb and Pfizer’s clotbuster Eliquis (apixaban) on the National Health Service in England and Wales.

In draft guidelines, the cost regulator has deemed Eliquis value for money when used for the treatment and prevention of venous thromboembolism (VTE) in adults.

For more details, go to: http://www.pharmatimes.com/Article/15-03-06/NICE_backs_BMS_Pfizer_bloodthinner_Eliquis_for_VTE.aspx?utm_source=dlvr.it&utm_medium=twitter